[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626606":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":32,"locations":39,"responsibleParty":54,"collaborators":56,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":26,"enrollmentInfo":70,"targetDuration":26,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":26,"overallStatus":79,"whyStopped":26,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"GCS Ramsay Santé pour l'Enseignement et la Recherche","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Neoadjuvant stereotactic radiotherapy","EXPERIMENTAL","Innovative treatment with neoadjuvant stereotactic radiotherapy, with the protocol requiring SRS to be performed 4 days ± 1 day before surgery to remove the target brain metastasis.\n\nNeuronavigation magnetic resonance imaging and a tracking scan, necessary for contouring the lesions and creating the treatment mask, will be performed within 7 days prior to the start of radiotherapy. These examinations are essential regardless of the type of stereotactic radiotherapy (adjuvant or neoadjuvant) and are routinely performed for lesion contouring.",[13,14],"Radiation: stereotactic radiotherapy","Procedure: Excision surgery",{"label":16,"type":17,"description":18,"interventionNames":19},"Control group : adjuvant stereotactic radiotherapy","ACTIVE_COMPARATOR","Standard care in accordance with the gold standard, with stereotactic radiotherapy performed as an adjunct to the surgical bed of the targeted lesion, i.e., 4 to 6 weeks after surgery. Neuronavigation magnetic resonance imaging and a tracking scan, necessary for contouring the lesions and creating the treatment mask, will be performed within 7 days prior to the start of radiotherapy.",[13,14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"RADIATION","stereotactic radiotherapy","Stereotactic radiotherapy is part of the standard treatment for brain metastases.",[16,9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"PROCEDURE","Excision surgery","Brain metastasis removal surgery",[16,9],[33],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"Philippe METELLUS, MD","CONTACT","04 91 17 14 83","+33","philippe.metellus@outlook.fr",[40],{"facility":41,"status":26,"city":42,"state":26,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Hôpital Privé Clairval","Marseille","13273","France","FR",{"type":47,"coordinates":48},"Point",[49,50],5.38107,43.29695,{"lat":50,"lon":49},[53],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},{"type":55,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[57],{"name":58,"class":59},"Euraxi Pharma","INDUSTRY","100626606","study-comparing-neoadjuvant-versus-adjuvant-stereotactic-radiotherapy-of-brain-metastases-100626606",false,"NCT07437820","Study Comparing Neoadjuvant Versus Adjuvant Stereotactic Radiotherapy of Brain Metastases","Prospective, Randomized, Multicenter Study Comparing the Efficacy and Tolerance of Neoadjuvant Versus Adjuvant Stereotactic Radiotherapy in the Management of Brain Metastases","NeoSRS","Inclusion Criteria:\n\n* Patients aged 18 years and older;\n* Patients with 1 to 12 brain metastases on preoperative MRI, at least one of which (contrast enhancement of at least 1 cm) is accessible for the most complete possible resection (target lesion);\n* Patients with a Karnofsky performance score of ≥ 70;\n* Patients able to perform neurocognitive tests without assistance;\n* Patients who understand the study and agree to attend all visits;\n* Patients who have signed a written informed consent form;\n* Affiliation with a social security system.\n\nExclusion Criteria:\n\n* Patient who has already been treated with surgery, radiosurgery, and\u002For radiotherapy for the target brain metastasis;\n* Medical contraindication to MRI;\n* Patient with an estimated life expectancy of ≤ 3 months;\n* Patients participating in another clinical trial, or who are in the exclusion period of another clinical trial;\n* Patients unable to complete a self-administered questionnaire;\n* Patients from a vulnerable population.","ALL","18 Years",{"count":71,"type":72},68,"ESTIMATED","INTERVENTIONAL",[75],"NA","The purpose of this study is to evaluate the local control rate on the target lesion at 6, 12, and 24 months after treatment with neoadjuvant stereotactic radiotherapy (SRS NEO group) compared to standard care, adjuvant stereotactic radiotherapy (POST OP SRS group).",[78],"Brain Metastases, Adult","NOT_YET_RECRUITING","2026-06-12",{"date":82,"type":83},"2026-06-15","ACTUAL",{"date":85,"type":72},"2026-07",{"date":87,"type":72},"2030-06-30",{"name":5,"class":6},1]